person · Reporting owner

BISCHOFBERGER NORBERT W

Disclosed activity across 4 companies

Tapewire entity: 16121
SEC CIK: 0001190273

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
GILEAD SCIENCES, INC.GILD · Entity 405	EVP, R&D and CSO	February 15, 2018	February 23, 2018
Vir Biotechnology, Inc.VIR · Entity 4522	Director	May 27, 2026	May 28, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

GILEAD SCIENCES, INC.

Report date February 15, 2018 · Filed February 23, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	19,602	Ending reported balance After 2018-02-21 transaction · row 5 5 source rows · reconciled sequence Row 1 · 2018-02-15 · Grant · Acquired 340 · Balance 12,793 F1: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. Row 2 · 2018-02-21 · Grant · Acquired 16,468 · Balance 29,261 F2: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 1, 2016, and February 2, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual satisfies the applicable service-vesting requirements by continuing in the Issuer's employ through December 31, 2018 and December 31, 2019, respectively. Row 3 · 2018-02-21 · Grant · Acquired 6,805 · Balance 36,066 F3: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2015. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. Row 4 · 2018-02-21 · Tax withholding · Disposed 7,071 · Balance 28,995 Row 5 · 2018-02-21 · Gift · Disposed 9,393 · Balance 19,602 F4: Shares gifted to family trust.
Common StockSEC Table I · non-derivative	IndirectBy Trust	2,317,800	Reported balance After 2018-02-21 transaction · row 6 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 6 · 2018-02-21 · Gift · Acquired 9,393 · Balance 2,317,800 F4: Shares gifted to family trust.

Filing footnotes · ownership attribution and instrument terms

F1: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan.

F2: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 1, 2016, and February 2, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual satisfies the applicable service-vesting requirements by continuing in the Issuer's employ through December 31, 2018 and December 31, 2019, respectively.

F3: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2015. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors.

F4: Shares gifted to family trust.

Vir Biotechnology, Inc.

Report date May 27, 2026 · Filed May 28, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	21,333	Reported balance After 2026-05-27 transaction · row 1 1 source row Row 1 · 2026-05-27 · Grant · Acquired 8,000 · Balance 21,333 F1: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan. F2: The RSUs will vest in full on May 27, 2027.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.10 · Expires 2036-05-26	Direct	16,000	Reported balance After 2026-05-27 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-05-27 · Grant · Acquired 16,000 · Balance 16,000 F4: The shares subject to the stock option will vest and become exercisable in full on May 27, 2027.
Common StockSEC Table I · non-derivative	IndirectSee footnote	10,667	Reported balance Holding disclosure · report date 2026-05-27 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 10,667 F3: The shares are held in the name of Nextquest, LLC, of which the Reporting Person is a managing member.

Filing footnotes · ownership attribution and instrument terms

F1: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.

F2: The RSUs will vest in full on May 27, 2027.

F3: The shares are held in the name of Nextquest, LLC, of which the Reporting Person is a managing member.

F4: The shares subject to the stock option will vest and become exercisable in full on May 27, 2027.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Kronos Bio, Inc.

Report date June 20, 2025 · Filed June 20, 2025

Section 16 reporting ended · disclosed 2025-06-20. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2025-06-20 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2025-06-20 · Other · Disposed 10,802,138 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2] F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price. F3: By the Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994,
Common StockSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2025-06-20 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2025-06-20 · Other · Disposed 263,750 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2] F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price. F4: By the Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The David Michael Anthony Dynasty GST Exempt Trust dated April 29, 2020.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2025-06-20 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2025-06-20 · Other · Disposed 263,750 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2] F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price. F5: By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The David Michael Anthony Dynasty GST Non-Exempt Trust dated April 29, 2020.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2025-06-20 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2025-06-20 · Other · Disposed 263,750 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2] F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price. F6: By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The Irene Alisha Bischofberger Dynasty GST Exempt Trust dated April 29, 2020.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2025-06-20 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2025-06-20 · Other · Disposed 263,750 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2] F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price. F7: By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The Irene Alisha Bischofberger Dynasty GST Non-Exempt Trust dated April 29, 2020.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.78 · Expires 2030-12-09	Direct	Reported balance After 2025-06-20 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-06-20 · Disposition to issuer · Disposed 297,186 · Balance 0 F8: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.30 · Expires 2032-02-15	Direct	Reported balance After 2025-06-20 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2025-06-20 · Disposition to issuer · Disposed 400,000 · Balance 0 F8: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.09 · Expires 2033-02-14	Direct	Reported balance After 2025-06-20 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2025-06-20 · Disposition to issuer · Disposed 570,868 · Balance 0 F8: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.08 · Expires 2034-02-14	Direct	Reported balance After 2025-06-20 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2025-06-20 · Disposition to issuer · Disposed 699,800 · Balance 0 F8: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2]

F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price.

F3: By the Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994,

F4: By the Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The David Michael Anthony Dynasty GST Exempt Trust dated April 29, 2020.

F5: By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The David Michael Anthony Dynasty GST Non-Exempt Trust dated April 29, 2020.

F6: By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The Irene Alisha Bischofberger Dynasty GST Exempt Trust dated April 29, 2020.

F7: By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The Irene Alisha Bischofberger Dynasty GST Non-Exempt Trust dated April 29, 2020.

F8: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.

Morphic Holding, Inc.

Report date August 16, 2024 · Filed August 20, 2024

Section 16 reporting ended · disclosed 2024-08-20. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2029-06-26	Direct	Reported balance After 2024-08-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-08-16 · Disposition to issuer · Disposed 24,000 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F4: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3: The Company Stock Option ("Option") is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.96 · Expires 2030-06-18	Direct	Reported balance After 2024-08-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-08-16 · Disposition to issuer · Disposed 12,000 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F4: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3: The Company Stock Option ("Option") is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.79 · Expires 2031-06-16	Direct	Reported balance After 2024-08-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-08-16 · Disposition to issuer · Disposed 9,888 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F4: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3: The Company Stock Option ("Option") is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.49 · Expires 2032-06-08	Direct	Reported balance After 2024-08-16 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-08-16 · Disposition to issuer · Disposed 17,550 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F4: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3: The Company Stock Option ("Option") is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.47 · Expires 2033-05-31	Direct	Reported balance After 2024-08-16 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-08-16 · Disposition to issuer · Disposed 12,535 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F4: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3: The Company Stock Option ("Option") is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.52 · Expires 2034-06-03	Direct	Reported balance After 2024-08-16 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-08-16 · Disposition to issuer · Disposed 23,168 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F4: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F5: The Option will vest in full on the earlier of (a) June 04, 2025 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.

F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding.

F3: The Company Stock Option ("Option") is fully vested.

F4: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof.

F5: The Option will vest in full on the earlier of (a) June 04, 2025 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 15, 2015 Filed Jan 20, 2015 17:46 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	70,000	$0.00 Strike: $16.40	$0.00	Disclosure SEC source: 0001179110-15-001042 · edgar.xml · derivative · entry 5 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 70,000 shares Expires 2017-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document
January 15, 2015 Filed Jan 20, 2015 17:46 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	11,679	$99.62	$1,163,418.77	Disclosure SEC source: 0001179110-15-001042 · edgar.xml · nonDerivative · entry 4 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,302 F5 · price: Sale prices reported for the transactions reported here range from $99.27 to $100.25. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request Read SEC document
January 15, 2015 Filed Jan 20, 2015 17:46 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	26,179	$98.77	$2,585,780.98	Disclosure SEC source: 0001179110-15-001042 · edgar.xml · nonDerivative · entry 3 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,981 F4 · price: Sale prices reported for the transactions reported here range from $98.27 to $99.25. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request Read SEC document
January 15, 2015 Filed Jan 20, 2015 17:46 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	32,142	$97.81	$3,143,882.95	Disclosure SEC source: 0001179110-15-001042 · edgar.xml · nonDerivative · entry 2 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,160 F3 · price: Sale prices reported for the transactions reported here range from $97.27 to $98.25. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document
January 15, 2015 Filed Jan 20, 2015 17:46 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionCommon Stock	70,000	$16.40	$1,147,650.00	Disclosure SEC source: 0001179110-15-001042 · edgar.xml · nonDerivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 06, 2014 Filed Aug 15, 2014 17:36 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GiftCommon Stock	4,000	$0.00	$0.00	Disclosure SEC source: 0001179110-14-012944 · edgar.xml · nonDerivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 2,154,681 F1 · shares: Gift of shares from family trust to charity. Read SEC document
June 16, 2014 Filed Jun 18, 2014 20:33 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	90,000	$0.00 Strike: $16.40	$0.00	Disclosure SEC source: 0001179110-14-010585 · edgar.xml · derivative · entry 3 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 90,000 shares Expires 2017-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document
June 16, 2014 Filed Jun 18, 2014 20:33 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	90,000	$80.90	$7,280,784.00	Disclosure SEC source: 0001179110-14-010585 · edgar.xml · nonDerivative · entry 2 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,302 F3 · price: Sale prices reported for the transactions reported here range from $81.35 to $80.42. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document
June 16, 2014 Filed Jun 18, 2014 20:33 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionCommon Stock	90,000	$16.40	$1,475,550.00	Disclosure SEC source: 0001179110-14-010585 · edgar.xml · nonDerivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 14, 2014 Filed May 16, 2014 18:52 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	90,000	$0.00 Strike: $16.40	$0.00	Disclosure SEC source: 0001179110-14-008608 · edgar.xml · derivative · entry 4 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 90,000 shares Expires 2017-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document
May 14, 2014 Filed May 16, 2014 18:52 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	41,336	$81.14	$3,354,122.91	Disclosure SEC source: 0001179110-14-008608 · edgar.xml · nonDerivative · entry 3 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,302 F4 · price: Sale prices reported for the transactions reported here range from $80.64 to $81.60. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document
May 14, 2014 Filed May 16, 2014 18:52 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	48,664	$80.24	$3,904,629.04	Disclosure SEC source: 0001179110-14-008608 · edgar.xml · nonDerivative · entry 2 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,638 F3 · price: Sale prices reported for the transactions reported here range from $79.64 to $80.63. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document
May 14, 2014 Filed May 16, 2014 18:52 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionCommon Stock	90,000	$16.40	$1,475,550.00	Disclosure SEC source: 0001179110-14-008608 · edgar.xml · nonDerivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 14, 2014 Filed Apr 16, 2014 16:34 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	90,000	$0.00 Strike: $16.40	$0.00	Disclosure SEC source: 0001179110-14-006849 · edgar.xml · derivative · entry 5 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,000 Underlying: Common Stock · 90,000 shares Expires 2017-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document
April 14, 2014 Filed Apr 16, 2014 16:34 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	7,703	$68.01	$523,853.30	Disclosure SEC source: 0001179110-14-006849 · edgar.xml · nonDerivative · entry 4 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,302 F5 · price: Sale prices reported for the transactions reported here range from $67.87 to $68.28. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document
April 14, 2014 Filed Apr 16, 2014 16:34 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	50,307	$67.23	$3,382,119.49	Disclosure SEC source: 0001179110-14-006849 · edgar.xml · nonDerivative · entry 3 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,005 F4 · price: Sale prices reported for the transactions reported here range from $66.87 to $67.85. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document
April 14, 2014 Filed Apr 16, 2014 16:34 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	31,990	$66.47	$2,126,509.66	Disclosure SEC source: 0001179110-14-006849 · edgar.xml · nonDerivative · entry 2 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,312 F3 · price: Sale prices reported for the transactions reported here range from $65.87 to $66.86. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document
April 14, 2014 Filed Apr 16, 2014 16:34 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionCommon Stock	90,000	$16.40	$1,475,550.00	Disclosure SEC source: 0001179110-14-006849 · edgar.xml · nonDerivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 14, 2014 Filed Mar 18, 2014 17:36 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	90,000	$0.00 Strike: $16.40	$0.00	Disclosure SEC source: 0001179110-14-005352 · edgar.xml · derivative · entry 5 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,000 Underlying: Common Stock · 90,000 shares Expires 2017-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document
March 14, 2014 Filed Mar 18, 2014 17:36 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	2,700	$76.83	$207,453.96	Disclosure SEC source: 0001179110-14-005352 · edgar.xml · nonDerivative · entry 4 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,302 F5 · price: Sale prices reported for the transactions reported here range from $76.80 to $76.95. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document
March 14, 2014 Filed Mar 18, 2014 17:36 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	48,488	$76.25	$3,697,433.04	Disclosure SEC source: 0001179110-14-005352 · edgar.xml · nonDerivative · entry 3 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,002 F4 · price: Sale prices reported for the transactions reported here range from $75.80 to $76.79. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document
March 14, 2014 Filed Mar 18, 2014 17:36 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	38,812	$75.36	$2,924,817.98	Disclosure SEC source: 0001179110-14-005352 · edgar.xml · nonDerivative · entry 2 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,490 F3 · price: Sale prices reported for the transactions reported here range from $74.80 to $75.79. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document
March 14, 2014 Filed Mar 18, 2014 17:36 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionCommon Stock	90,000	$16.40	$1,475,550.00	Disclosure SEC source: 0001179110-14-005352 · edgar.xml · nonDerivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 06, 2014 Filed Mar 10, 2014 20:15 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Tax withholdingCommon Stock	54,790	$79.92	$4,378,816.80	Disclosure SEC source: 0001179110-14-004896 · edgar.xml · nonDerivative · entry 3 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,302 Read SEC document
March 06, 2014 Filed Mar 10, 2014 20:15 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantCommon Stock	105,000	$0.00	$0.00	Disclosure SEC source: 0001179110-14-004896 · edgar.xml · nonDerivative · entry 2 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,092 F2 · shares: Vesting of performance share awards on March 6, 2014 Read SEC document
February 14, 2014 Filed Feb 19, 2014 19:09 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	90,000	$0.00 Strike: $14.50	$0.00	Disclosure SEC source: 0001179110-14-003052 · edgar.xml · derivative · entry 5 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,000 shares Expires 2016-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document
February 14, 2014 Filed Feb 19, 2014 19:09 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	3,900	$82.75	$322,723.44	Disclosure SEC source: 0001179110-14-003052 · edgar.xml · nonDerivative · entry 4 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,124 F5 · price: Sale prices reported for the transactions reported here range from $82.65 to $82.84. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document
February 14, 2014 Filed Feb 19, 2014 19:09 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	13,586	$81.99	$1,113,884.89	Disclosure SEC source: 0001179110-14-003052 · edgar.xml · nonDerivative · entry 3 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,024 F4 · price: Sale prices reported for the transactions reported here range from $81.65 to $82.62. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document
February 14, 2014 Filed Feb 19, 2014 19:09 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	72,514	$81.17	$5,885,613.31	Disclosure SEC source: 0001179110-14-003052 · edgar.xml · nonDerivative · entry 2 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,610 F3 · price: Sale prices reported for the transactions reported here range from $80.65 to $81.64. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document
February 14, 2014 Filed Feb 19, 2014 19:09 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionCommon Stock	90,000	$14.50	$1,305,225.00	Disclosure SEC source: 0001179110-14-003052 · edgar.xml · nonDerivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,124 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 14, 2014 Filed Mar 10, 2014 20:15 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantCommon Stock	968	$21.94	$21,242.66	Disclosure SEC source: 0001179110-14-004896 · edgar.xml · nonDerivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,092 F1 · shares: Amount of securities beneficially owned acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan on February 14, 2014. Read SEC document
February 01, 2014 Filed Feb 5, 2014 01:19 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantNon-Qualified Stock Option (right to buy) · Derivative	57,180	$0.00 Strike: $80.65	$0.00	Disclosure SEC source: 0001179110-14-001951 · edgar.xml · derivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,180 Underlying: Common Stock · 57,180 shares Expires 2024-02-01 F1 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document
January 23, 2014 Filed Jan 27, 2014 23:46 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantCommon Stock	14,792	$0.00	$0.00	Disclosure SEC source: 0001179110-14-001415 · edgar.xml · nonDerivative · entry 2 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,124 F2 · shares: Represents shares of the Issuer's common stock subject to a specific tranche of the performance share award made to the Reporting Person on February 1, 2013. Such tranche of shares was subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was deemed satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be actually issued to the Reporting Person until such individual satisfies the applicable service-vesting requirement by continuing in the Issuer's employ through December 31, 2015. Read SEC document
January 23, 2014 Filed Jan 27, 2014 23:46 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantCommon Stock	26,666	$0.00	$0.00	Disclosure SEC source: 0001179110-14-001415 · edgar.xml · nonDerivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,332 F1 · shares: Represents shares of the Issuer's common stock subject to a specific tranche of the performance share award made to the Reporting Person on January 26, 2012. Such tranche of shares was subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was deemed satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be actually issued to the Reporting Person until such individual satisfies the applicable service-vesting requirement by continuing in the Issuer's employ through December 31, 2014. Read SEC document
January 14, 2014 Filed Jan 16, 2014 19:15 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionNon-Qualified Stock option (right to buy) · Derivative	90,000	$0.00 Strike: $14.50	$0.00	Disclosure SEC source: 0001179110-14-001079 · edgar.xml · derivative · entry 5 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2016-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document
January 14, 2014 Filed Jan 16, 2014 19:15 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	24,851	$75.02	$1,864,344.39	Disclosure SEC source: 0001179110-14-001079 · edgar.xml · nonDerivative · entry 4 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F5 · price: Sale prices reported for the transactions reported here range from $74.92 to $75.16. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document
January 14, 2014 Filed Jan 16, 2014 19:15 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	27,078	$74.41	$2,014,933.55	Disclosure SEC source: 0001179110-14-001079 · edgar.xml · nonDerivative · entry 3 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,851 F4 · price: Sale prices reported for the transactions reported here range from $73.92 to $74.9185. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document
January 14, 2014 Filed Jan 16, 2014 19:15 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	38,071	$73.60	$2,801,869.51	Disclosure SEC source: 0001179110-14-001079 · edgar.xml · nonDerivative · entry 2 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,929 F3 · price: Sale prices reported for the transactions reported here range from $72.92 to $73.91. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document
January 14, 2014 Filed Jan 16, 2014 19:15 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionCommon Stock	90,000	$14.50	$1,305,225.00	Disclosure SEC source: 0001179110-14-001079 · edgar.xml · nonDerivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 16, 2013 Filed Dec 18, 2013 19:16 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionNon-Qualified Stock option (right to buy) · Derivative	90,000	$0.00 Strike: $14.50	$0.00	Disclosure SEC source: 0001179110-13-018252 · edgar.xml · derivative · entry 3 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 90,000 shares Expires 2016-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document
December 16, 2013 Filed Dec 18, 2013 19:16 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	90,000	$71.75	$6,457,941.00	Disclosure SEC source: 0001179110-13-018252 · edgar.xml · nonDerivative · entry 2 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: Sale prices reported for the transactions reported here range from $71.43 to $72.34. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document
December 16, 2013 Filed Dec 18, 2013 19:16 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionCommon Stock	90,000	$14.50	$1,305,225.00	Disclosure SEC source: 0001179110-13-018252 · edgar.xml · nonDerivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 14, 2013 Filed Nov 18, 2013 20:12 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionNon-Qualified Stock option (right to buy) · Derivative	90,000	$0.00 Strike: $14.50	$0.00	Disclosure SEC source: 0001179110-13-016632 · edgar.xml · derivative · entry 4 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,000 Underlying: Common Stock · 90,000 shares Expires 2016-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document
November 14, 2013 Filed Nov 18, 2013 20:12 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GiftCommon Stock	4,000	$0.00	$0.00	Disclosure SEC source: 0001179110-13-016632 · edgar.xml · nonDerivative · entry 3 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 2,158,681 F4 · kind: Shares gifted to a donor advised fund. Read SEC document
November 14, 2013 Filed Nov 18, 2013 20:12 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	90,000	$68.86	$6,197,292.00	Disclosure SEC source: 0001179110-13-016632 · edgar.xml · nonDerivative · entry 2 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: Sale prices reported for the transactions reported here range from $68.59 to $69.24. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document
November 14, 2013 Filed Nov 18, 2013 20:12 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionCommon Stock	90,000	$14.50	$1,305,225.00	Disclosure SEC source: 0001179110-13-016632 · edgar.xml · nonDerivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 14, 2013 Filed Oct 16, 2013 22:05 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionNon-Qualified Stock option (right to buy) · Derivative	90,000	$0.00 Strike: $14.50	$0.00	Disclosure SEC source: 0001179110-13-015563 · edgar.xml · derivative · entry 4 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,000 Underlying: Common Stock · 90,000 shares Expires 2016-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document
October 14, 2013 Filed Oct 16, 2013 22:05 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	14,147	$63.29	$895,430.12	Disclosure SEC source: 0001179110-13-015563 · edgar.xml · nonDerivative · entry 3 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,159,643 F4 · price: Sale prices reported for the transactions reported here range from $63.0359 to $63.47. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document
October 14, 2013 Filed Oct 16, 2013 22:05 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	75,853	$62.39	$4,732,756.91	Disclosure SEC source: 0001179110-13-015563 · edgar.xml · nonDerivative · entry 2 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,173,790 F3 · price: Sale prices reported for the transactions reported here range from $62.02 to $62.9728. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document
October 14, 2013 Filed Oct 16, 2013 22:05 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionCommon Stock	90,000	$14.50	$1,305,225.00	Disclosure SEC source: 0001179110-13-015563 · edgar.xml · nonDerivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,249,643 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.